Literature DB >> 15046612

PI 3-kinase inhibition: a therapeutic target for respiratory disease.

P M Finan1, M J Thomas.   

Abstract

Asthma and COPD (chronic obstructive pulmonary disease) are a growing major health burden, which, despite improvements in disease management, still require new effective treatments. As our understanding of the cellular and molecular processes which govern respiratory diseases improves, the range of potential therapeutic targets increase. PI 3-kinases (phosphoinositide 3-kinases) are a family of closely related enzymes, which play pivotal roles in a diverse array of cellular mechanisms. In the present paper, we review the evidence for PI 3-kinase involvement in various cellular processes underlying asthma and COPD generated through inhibitor studies and gene-targeting approaches, and discuss the prospects for PI 3-kinase inhibition as a future therapeutic strategy for the treatment of respiratory disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15046612     DOI: 10.1042/bst0320378

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  7 in total

Review 1.  Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond.

Authors:  David A Medina-Tato; Stephen G Ward; Malcolm L Watson
Journal:  Immunology       Date:  2007-08       Impact factor: 7.397

2.  Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.

Authors:  Matthias Niedermeier; Bryan T Hennessy; Zachary A Knight; Marina Henneberg; Jianhua Hu; Antonina V Kurtova; William G Wierda; Michael J Keating; Kevan M Shokat; Jan A Burger
Journal:  Blood       Date:  2009-03-24       Impact factor: 22.113

Review 3.  Phosphoinositide 3-Kinase in Asthma: Novel Roles and Therapeutic Approaches.

Authors:  Edwin J Yoo; Christie A Ojiaku; Krishna Sunder; Reynold A Panettieri
Journal:  Am J Respir Cell Mol Biol       Date:  2017-06       Impact factor: 6.914

4.  Design and Development of a Macrocyclic Series Targeting Phosphoinositide 3-Kinase δ.

Authors:  Jonathan A Spencer; Ian R Baldwin; Nick Barton; Chun-Wa Chung; Máire A Convery; Christopher D Edwards; Craig Jamieson; David N Mallett; James E Rowedder; Paul Rowland; Daniel A Thomas; Charlotte J Hardy
Journal:  ACS Med Chem Lett       Date:  2020-06-03       Impact factor: 4.345

5.  A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.

Authors:  Neil E Torbett; Antonio Luna-Moran; Zachary A Knight; Andrew Houk; Mark Moasser; William Weiss; Kevan M Shokat; David Stokoe
Journal:  Biochem J       Date:  2008-10-01       Impact factor: 3.857

6.  Slow self-activation enhances the potency of viridin prodrugs.

Authors:  Joseph Blois; Hushan Yuan; Adam Smith; Michael E Pacold; Ralph Weissleder; Lewis C Cantley; Lee Josephson
Journal:  J Med Chem       Date:  2008-07-17       Impact factor: 7.446

Review 7.  A review on the development of urease inhibitors as antimicrobial agents against pathogenic bacteria.

Authors:  Yuri F Rego; Marcelo P Queiroz; Tiago O Brito; Priscila G Carvalho; Vagner T de Queiroz; Ângelo de Fátima; Fernando Macedo
Journal:  J Adv Res       Date:  2018-05-04       Impact factor: 10.479

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.